PoliticsMoneycontrol
Not practical to shift generic drug manufacturing to US: Dr Reddy's CEO on Trump's tariff plan
in5points
Dr Reddy's CEO GV Prasad said shifting generic drug manufacturing to the US is not practical under Trump's tariff plan.
Prasad stated the company will not take special action due to the announcement but will learn and evolve accordingly.
The CEO emphasized the impracticality of moving manufacturing given existing cost structures and supply chains.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Moneycontrol
Center-right
Mixed factuality
